natgillin/translations-raw huggingface dataset:
In a further embodiment the follicle-stimulating hormone (FSH) is present at a concentration of at or about 0.37 to 2 ug/mg of the total formulation. 
Smrzavanjem osušena formulacija prema zahtjevu 7, naznačena time da je folikulostimulirajući hormon (FSH) prisutan u koncentraciji od ili oko 0.37 do 2 ug/mg ukupne formulacije.
The recombinant proteins are secreted by the cells into the cell culture medium, into the milk or are present in cell lysates and must be separated from other cell components, such as cell waste products, cell debris and proteins or other collected material. 
Stanice izlučuju rekombinantne proteine u hranjivi medij, u mlijeko, ili su takvi proteini prisutni u staničnim lizatima te ih se mora odvojiti od drugih staničnih komponenti, poput otpadnih tvari, ostataka stanica i proteina ili drugog sakupljenog materijala.
The method of claim 1, wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof is provided as a single agent or in combination with another pharmaceutical agent in a newly diagnosed hematologic malignant proliferative disorder pediatric patient, to maintain remission, or a relapsed/refractory hematologic malignant proliferative disorder pediatric patient. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu je terapeutski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli osigurana kao jedini agens ili u kombinaciji s drugim farmaceutskim agensom pedijatrijskom subjektu s novodijagnosticiranom akutnom mijeloičnom leukemijom (AML), za održavanje remisije kod pedijatrijskog subjekta ili subjekta s relapsiranom ili refraktornom akutnom mijeloičnom leukemijom (AML).
converting an intermediate of formula (XIX) in the presence of a strong acid in a suitable solvent to obtain compounds of formula (III) with the variables as defined in claim 1; 
OH sa varijablama kako je definirano u zahtjevu I; konverziju intermedijera prema formuli (XIX) u prisutnosti jake kiseline u prikladnom otapalu da se dobiju spojevi formule (III)
The process according to claim 13, characterized in that the dispersing agent is added prior to the concentrating step. 
Postupak prema zahtjevu 13, naznačen time što se disperzno sredstvo dodaje prije koraka koncentriranja.
reacting 2,2-dimethyl-1,3 dioxolane-4-carbaldehyde of formula with a vinyl Grignard reagent to obtain a compound of formula IIb in the form of diastereomeric mixture (R,S+S,S) 
I) reakciju 2,2-dimetil-1,3dioksolan-4-karbaldehida formule dq s vinil Grignardovim reagensom, da bi se dobio spoj formule IIb u obliku dijasteroizomerne smjese (R, S+8, S) on
The composition of any of claims 1 to 5, comprising PTH at a concentration of 1.4 mg/ml, methionine at a concentration of 2 mg/ml, a poloxamer at a concentration of 0.3 mg/ml, and a physiologically acceptable buffering agent that maintains the pH of the formulation at a pH of 5.5. 
Sastav prema bilo kojem zahtjevu 1 do 5, naznačen time, da sadrži PTH u koncentraciji od 1,4 mg/ml, metionin u koncentraciji od 2 mg/ml, poloksamcr u koncentraciji od 0,3 mg/ml, i fiziološki prihvatljivo pufersko sredstvo koje održava pH formulacije na pH 5,5.
The use of a kit in the diagnosis of Graft versus Host Disease, GVHD, said kit comprising a protein chip comprising an array of bound antibodies recognizing biomarkers characteristic of GVHD, said biomarkers are selected from the group comprising Total GSK-3B, serine 9 phosphorylated GSK-3B, GSK-3B serine 9 phosphorylation PKC activation, GSK-3B tyrosine 216 phosphorylation, for determining the expression levels of different GVHD relevant proteins in a given sample. 
Korištenje kompleta u dijagnozi Graft versus Host Disease, GVHD, pri čemu navedeni komplet sadrži proteinski čip koji sadrži niz vezanih protutijela koja prepoznaju biomarkere karakteristične za GVHD, pri čemu su navedeni biomarkeri odabrani iz skupine koja obuhvaća Total GSK3B, serin 9 fosforiliran GSK-3B, PKK aktivaciju fosforilacije GSK-3B serina 9, fosforilacija GSK-3B tirozina 216, za određivanje razina ekspresije različitih GVHD relevantnih proteina u danom uzorku.
In some embodiments, Y4 is nitrogen and R8 is absent. 
Y? je dušik i R' je odsutan; i svaki n je 0 ili 1.
A pharmaceutical composition according to claim 7, which is a dosage unit comprising 20 to 300 mg or 30 to 200 mg of a high purity diaminophenothiazinium compound according to any one of claims 1 to 6, and a pharmaceutically acceptable carrier, diluent, or excipient. 
Farmaceutska tableta ili kapsula, naznačena time, da obuhvaća od 20 do 300 mg ili od 30 do 200 mg diaminofenotiazinskog spoja visoke čistoće prema bilo kojem od zahtjeva 1 do 8, i farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćnu tvar.
In accordance with the invention there is provided a long-term storage stable non-aqueous liquid bendamustine-containing composition, comprising: a) bendamustine or a pharmaceutically acceptable salt thereof; and b) a pharmaceutically acceptable fluid comprising: i) polyethylene glycol, propylene glycol, or mixtures thereof; and ii) a stabilizing amount of an antioxidant. 
HR P20161771 T1 PATENTNI ZAHTJEVI 1. Stabilan pri dugotrajnom skladištenju, nevodeni tekući pripravak s bendamustinom koji sadrži: a) - bendamustin ili njegovu farmaceutski prihvatljivu sol; i b) - farmaceutski prihvatljivu tekućinu koja sadrži: i) polietilen glikol, propilen glikol ili njihovu smjesu; i ii) stabilizirajuću količinu antioksidansa.
The method according to one or more of the preceding claims 15 to 26, characterized in that the coating yarn or yarns of said elastomer yam (1a) used to provide said first rows of knitting (1) is made of polyamide or natural fibers. 
Postupak prema jednom ili više prethodnih zahtjeva 15 do 26, naznačen time, da je konac za prevlačenje, odnosno da su konci za prevlačenje spomenutog elastomernog konca (1a), upotrijebljenog za izradu neparnih redova pletiva (1), izrađen od poliamidnih vlakana ili prirodnih vlakana.
This may serve to hide the outflow opening from view. In such an embodiment the air scenting device may further comprising a foot configured to support housing thereon, wherein the foot exhibits a smaller horizontal circumferential size than the housing and the outflow opening is arranged in or at least partially around the foot. 
Sklop u skladu sa patentnim zahtjevom 2, koji dalje sadrži bazu (4) konfiguriranu da podrži kućište (2, 14) na njoj, gdje navedena baza (4) ima manju vodoravnu obodnu veličinu od navedenog kućišta i navedeni otvor za otpuštanje je raspoređen u ili najmanje djelomično oko navedene baze.
In one embodiment, the method comprises administering to a human a T cell genetically engineered to express a CAR wherein the CAR comprises an antigen binding domain, a costimulatory signaling region, and a CD3 zeta signaling domain comprising the amino acid sequence of SEQ ID NO: 24, wherein the persisting population of genetically engineered T cells persists in the human for at least one month after administration. 
T stanica koja je genetski modificirana tako da eksprimira CAR, naznačena time što CAR sadrži (a) antigen- vezujuću domenu koja predstavlja anti-CD19 scFv koji sadrži aminokiselinsku sekvencu SEQ ID NO:20, (b) kostimulatornu signalnu regiju 4-1BB, i (c) signalnu domenu CD3 zeta koja sadrži aminokiselinsku sekvencu SEQ ID NO: 24, za upotrebu u postupku za liječenje karcinoma kod čovjeka, pri čemu dolazi do remisije karcinoma, i pri čemu je čovjek otporan na liječenje najmanje jednim kemoterapeutskim sredstvom.
—SO2NR3aR3b, wherein R3a, and R3b are independently selected from the group consisting of 
(12)-NRxCORs, gdje Ra,1 Ray su neovisno odabrani iz skupine koja sadrži
in a compatible solvent to stereoselectively produce a compound of formula (I). 
ČHs u kompatibilnom otapalu da se stereoselektivno proizvede spoj formule (1).
The cellulose reactive glyoxalated copolymer composition of claim 1, wherein the glyoxalated copolymer composition comprises about 1 to about 3 weight % of the glyoxalated copolymer, based on the total weight of the aqueous medium. 
Sastav glioksaliranog kopolimera reaktivnog sa celulozom prema zahtjevu 1, gdje sastav glioksaliranog kopolimera sadrži 1 do 3 masena % glioksaliranog kopolimera, zasnovano na ukupnoj masi vodenog medija.
adding (L)-Arginine and heating the reaction mass to reflux temperature, 
zagrijavanje reakcijske mase do temperature refluksa,
The method according to claim 9, wherein the vaccine is an Inactivated Polio Vaccine (IPV). 
Postupak prema patentnom zahtjevu 10, naznačen time što je cjepivo inaktivirano polio cjepivo (IPV).
The isolated nucleic acid of claim 13, wherein the nucleic acid further encodes a ligand which specifically binds to an antigen or receptor on a cell surface, wherein the ligand is fused directly or through a peptide linker to the PE. The isolated nucleic acid of claim 14, wherein the ligand is an antibody or fragment thereof which has antigen binding capability. 
Izolirana nukleinska kiselina iz zahtjeva 12, nadalje naznačena time da ta nukleinska kiselina kodira citokin, antitijelo ili fragment antitijela koji se specifično veže na neki antigen ili receptor na spomenutoj površini stanice, koji se citotokin, antitijelo ili fragment antitijela fuzionira na spomenuti mutirani PE bilo direktno ili preko neke peptidne veze.
The pharmaceutical preparation according to the invention can be produced by processes familiar to the skilled person. 
Farmaceutski pripravak prema izumu se može pripremiti postupcima koji su poznati stručnjacima iz struke.
In an aspect of the method, the method further comprises the step of assigning to the subject the likelihood of having an adverse reaction to telomerase inhibitor treatment. 
Postupak prema zahtjevu 1, pri čemu postupak nadalje obuhvaća korak dodjeljivanja subjektu vjerojatnosti razvitka nuspojave na liječenje terapijom inhibicije telomeraze.
Process according to any of the preceding claims, wherein solvent C is selected from the group consisting of 1-butanol, isopropanol, isobutanol and 1-pentanol, 
Postupak prema jednom od prethodnih zahtjeva, naznačeno time da je otapalo C odabrano iz skupine, koja se sastoji od 1-butanola, izopropanola, izobutanola i 1-pentanola.
General embodiments of the disclosure therefore include: 
Broj objave europskog patenta:
mixing all of said coarse particles of a physiologically acceptable excipient; all of said magnesium stearate; a first portion of said micronized particles of a physiologically acceptable excipient; and all of said micronized particles of glycopyrronium bromide, beclometasone dipropionate, and formoterol fumarate dihydrate in a vessel of a shaker mixer at a speed of rotation of 20 to 28 rpm for a time of 60 to 120 minutes, to obtain a first mixture; and 
miješanje svih rečenih grubih čestica fiziološki prihvatljivog ekscipijensa, svog rečenog magnezijeva stearata, prvog dijela rečenih mikroniziranih čestica fiziološki prihvatljivog ekscipijensa, svih rečenih mikroniziranih čestica glikopironijeva bromida, beklometazon-dipropionata, te formoterol-fumarat dihidrata u posudi miješalice s potresivanjem pri brzini rotacije ne manjoj od 16 rpm u vremenu ne manjem od 60 minuta, da se dobije prva smjesa; te
receive a special data packet with an end marker from the SGW through an S1 interface, which connects the source eNB and the SGW, after the path switching, wherein the special data packet received from the SGW does not contain user data, and the end marker in the special data packet received from the SGW is set in a header of the special data packet received from the SGW to indicate that the special data packet is the last data packet sent from the SGW to the source eNB; and 
LTE mreža prema zahtjevu 5, naznačena time da je SGW konfiguriran da generira poseban paket podataka i šalje poseban paket podataka prema izvorišnom eNB nakon što SGW provede komutaciju puta; i izvorišni eNB je konfiguriran da prosljeđuje poseban paket podataka prema ciljnom eNB nakon prijema posebnog paketa podataka poslanog od SGW.
Reference 57 discloses substitutions Arg-38-Ala and Phe-42-Lys in order to reduce toxicity for use during immunotherapy. 
Referenca 57 otkriva supstitucije Arg-38-Ala i Phe-42-Lys da bi se smanjila toksičnost za uporabu za vrijeme imunoterapije.
These compounds are disclosed to have an effect on one or mote enzymes that utilize folic acid and its metabolic derivatives as a substrate. 
Za ove spojeve otkriveno je da imaju učinak na jedan ili više enzima koji kao supstrat koriste folnu kiselinu i njene metaboličke derivate.
Add 100 µl of a KG-1 cell suspension at 1×106 cells/ml to all the wells of the 96 well plate. 
Dodaj 100 ul suspenzije stanica KG-1 koncentracije 1x105 po jažici/ml svim jažicama pločici s 96 jažica. HR P20070196 T3
The image processing apparatus according to any of claims 1 to 7, wherein the isotropic blurring device (14) changes a shape or a size of the isotropic smoothing filter in accordance with the information representing the amount of exposure of the original image (P0) upon radiography, or the anisotropic blurring device (15) changes a shape or a size of the anisotropic smoothing filter in accordance with the information representing the amount of exposure of the original image (P0) upon radiography. 
Uređaj za obradu slike prema bilo kojem od zahtjeva 1 do 7, naznačen time, da uređaj za izotropno zamagljenje (14) mijenja oblik ili veličinu izotropnog filtera za omekšavanje šuma u skladu s informacijom koja predstavlja količinu ekspozicije originalne slike (PO) nakon radiografije, ili uređaj za neizotropno zamagljenje (15) mijenja oblik ili veličinu neizotropnog filtera za omekšavanje šuma u skladu s informacijom koja predstavlja količinu ekspozicije originalne slike (PO) nakon radiografije.
The imaging material supply cartridge (24) of claim 1 further comprising one or more print heads. 
Spremišna patrona za materijal za pisanje (24) u skladu s patentnim zahtjevom 1, naznačena time što dodatno sadrži jednu ili više glava pisača.
is selected from the following groups: H, CH3, 
R, je odabran od sljedećih: H, CH,, ili odgovarajuće farmaceutski prihvatljive soli.
In a preferred embodiment of the present invention the increase in residence time of rifaximin formulation in the gastrointestinal tract is achieved by bioadhesion wherein bioadhesion is achieved using polymers having affinity for gastrointestinal mucosa. 
Oralni farmaceutski pripravak s kontroliranim oslobađanjem prema zahtjevu 2, naznačen time da se produljenje vremena zadržavanja rifaksimina u probavnom sustavu postiže bioadhezijom.
It promotes even distribution into the space through which forage 8 is moving (see reference no. 28 in Fig. 2). 
Ona osigurava ravnomjernu raspodjelu u prostoru kroz koji se krupna stočna hrana 8 kreće (vidjeti element 28 na slici 2).
The combination drug according to any one of [9] to [12], wherein one cycle of an administration schedule, in which, in a period of 28 days, the combination drug containing trifluridine and tipiracil hydrochloride in a molar ratio of 1:0.5 is administered on Days 1 to 5 and on Days 8 to 12, and CPT-11 is administered on Days 1 and 15, is repeated once or twice or more times. 
Kombinirani lijek za primjenu u skladu sa bilo kojim od patentnih zahtjeva 7 do 10, gdje jedan ciklus rasporeda administracije, u kome, u periodu od 28 dana, kombinirani lijek koji sadrži trifluridin i tipiracil hidroklorid u molarnom odnosu od 1:0.5 je administriran na Dane 1 do 5 i na Dane 8 do 12, i CPT-I11 je administriran na Dane 1 i 15, je ponovljen jednom ili dva puta ili više puta.
Thus, for example, RS is a shorthand notation for 3 R,11 bS . 
Tako je, na primjer, RS skraćenica za 3R,11bS.
A method for preparing a vaccine kit comprising preparing an emulsion according to any one of claims 1 to 9 and packaging the emulsion into a kit as a kit component together with an antigen component. 
Metoda za pripremu kompleta cjepiva, naznačena time da uključuje pripremu emulzije prema bilo kojem zahtjevu od 1 do 11 i pakiranje emulzije u komplet kao komponente kompleta zajedno s komponentom antigena.
The immunogenic composition for use according to any one of claims 1-3 wherein the Streptococcus pneumoniae infection occurs in the meninges and the concentration of Zn2+ in the cerebrospinal fluid is less than 1.5, 1, 0.75, 0.5, 0.25 or 0.1 µM or less than 100, 75, 50, 25, or 10µg/L. 
Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što do infekcije bakterijom Streptococcus pneumoniae dolazi u moždanim ovojnicama, a koncentracija Zn"* u cerebrospinalnoj tekućini je manja od 1,5, 1, 0,75, 0,5, 0,25 ili 0,1 uM ili manja od 100, 75, 50, 25 ili 10 ug/1.
For example, for parenteral administration, the active protein(s) may be formulated in a unit dosage form for injection in vehicles such as saline, dextrose solution, serum albumin and Ringer's solution. 
Na primjer, za parenteralnu primjenu, aktivni protein(i) može biti formuliran u jediničnim doziranjima za injektiranje u nosivoj tvari poput solne otopine, otopine dekstroze, serumskog albumina i Ringerovoj otopini.
For example, tetrabutylammonium salts of the invention may be prepared by dissolving the Na+-salt in water containing tetrabutylammonium sulfate followed by extraction of the tetrabutylammonium salt I into a methylene chloride phase, and subsequent isolation of the tetrabutylammonium salt I. In this manner also other tetraalkylammonium salts I may be prepared. 
Na primjer, tetrabutilamonij soli iz ovog izuma mogu se dobiti otapanjem Na' - soli u vodi koja sadrži tetrabutilamonij sulfat, zatim ekstrakcijom tetrabutilamonij soli [| u metilen kloridnu fazu i slijedeće izolacijom tetrabutilamonij soli I. Na ovaj način mogu se također dobiti i druge tetraalkilamonij soli I.
Process according to claim 11, characterised in that said SNGCC of step a) is provided in the form of an aqueous suspension or dispersion. 
Postupak u skladu s patentnim zahtjevom 10, karakteriziran na način da je navedeni SNGCC iz koraka a) omogućen u obliku vodene otopine ili disperzije.
In a 100 flask fitted with reflux cooler, thermometer and magnetic stirrer, 2.77 g (8.6 mmol) of 2,2′-dithio-diisosorbide (10) obtained according to Example 8 are dissolved in 17 ml, of acetic acid and 3.5 mL of acetic anhydride are added. 
U tikvici od 100 mL, opremljenoj s povratnim hladilom, termometrom i magnetskom mješalicom, 2,77 g (8,6 mmolova) 2,2'-ditio-diizo-sorbida (10) dobivenog prema primjeru 8 se otopi u 17 mL octene kiseline 1 doda se 3,5 mL octenog anhidrida.
The compound for use of claim 1, wherein the disease or disorder is multiple myeloma. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak jetre.
Utilizing compound (AS), a variety of substituents (wherein R′ is C1-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl) can be introduced at C-5 as shown in Reaction Scheme VI. 
Korištenjem spoja (AS), različiti supstituendi (gdje R' je C,4 alkil, C24 alkenil i C24 alkinil) se mogu uvesti na C-5 kao što to prikazuje Reakcijska Shema VI. Geheme VI e 2 f
water is added to the melphalan flufenamide solution in order to obtain an aqueous melphalan flufenamide solution, in a concentration of about 0.2-3.0 mg/ml; 
dodaje se voda otopini melfalan flufenamid hidroklorida (J1) da bi se dobila vodena otopina melfalan flufenamid hidroklorida (J1), u koncentraciji od 0,2 - 3,0 mg/ml;
providing a mammalian cell comprising an exogenous recombinant nucleic acid comprising the nucleotide sequence encoding human vitamin K reductase complex subunit 1 (VKORC1) inserted into a plasmid integrated into its genome; 
(a) dobavljanje organizma domačina s rekombinantnom nukleinskom kiselinom, koja kodira za kompleksnu podjedinicu 1 reduktaze vitamina K (VKORC1), integriranom u njegovom genomu;
The molecule for use according to claim 7, wherein the condition is liver disease. 
Molekula za upotrebu u skladu s patentnim zahtjevom 7, naznačena time, da je navedeno stanje bolest jetre.
A compound of claim 1, which is selected from the group consisting of and or a pharmaceutically acceptable salt of any of the foregoing. 
Spoj prema zahtjevu 1, naznačen time da je odabran iz skupine koja sadrži Spoj £1đa, Spojiiša, ili farmaceutski prihvatljiva sol bilo kojeg od prethodno navedenih.
For some time, inhalers have been known for delivering metered doses of medicament from aerosol canisters through a nozzle. 
Neko se vrijeme već koriste inhalatori za odmjeravanje doza medikamenta iz aerosolnog spremnika kroz raspršivač.
The integrated circuit according to claim 1 wherein Localized Virtual Resource Blocks (LVRBs), which are mapped to PRBs, are allocated by units of RBGs. 
Integrirani krug sukladno jednom od zahtjeva 1 do 9, naznačen time da su u drugoj dodjeli, lokaliziram virtualni blokovi resursa, LVRB-ovi, mapirani na PRB-ove, i LVRB-ovi su dodijeljeni uređaju mobilnoj stanici u jedinicama RBG-a.
The immunocytokine of claim 1, wherein said derivative of the sushi domain of the IL-15Ra has at least 25%, more preferably at least 50% of the binding activity of the sushi domain of human IL-15Ra, or has an amino acid sequence having a percentage of identity of at least 92% with an amino acid sequence in the group consisting of SEQ ID n°:4, SEQ ID n°:5, SEQ ID n°:6, SEQ ID n°:7, SEQ ID n°:8, and SEQ ID n°:9, preferably of at least 96%, and more preferably of at least 98%. 
Imunocitokin prema zahtjevu 1, naznačen time što navedeni derivat „sushi domain“ IL-15Ra ima najmanje 25 %, poželjnije najmanje 50 % aktivnosti vezanja „sushi domain“ ljudskog IL-15Ra, ili ima aminokiselinsku sekvencu koja ima postotak identičnosti od barem 92 % s aminokiselinskom sekvencom iz skupine koja se sastoji od SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8 i SEQ ID NO 9, poželjnije od najmanje 96 % i još poželjnije najmanje 98 %.
A chimeric molecule comprising a ligand which specifically binds to an antigen or receptor on a cell surface, conjugated or fused to 
(a) citokin, antitijelo ili fragment antitijela, koji se citokin, antitijelo ili fragment antitijela specifično veže na neki antigen ili receptor na površini stanice, konjugiran ili fuzioniran sa:
The antibody for use according to any one of claims 1-5, wherein there is a post-administration reduction in absolute basophil count of at least about 5, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, or at least about 70 basophils/mm3. 
Protutijelo za upotrebu prema bilo kojem od zahtjeva 1 do 5, naznačeno time da postoji smanjenje apsolutnog broja eozinofila nakon davanja od najmanje oko 25, najmanje oko 50, najmanje oko 75, najmanje oko 100, najmanje oko 125, najmanje oko 150, najmanje oko 175, najmanje oko 200, najmanje oko 225, najmanje oko 250, najmanje oko 275, najmanje oko 300, najmanje oko 325, najmanje oko 350, najmanje oko 375, najmanje oko 400, najmanje oko 425, najmanje oko 450, najmanje oko 475, ili najmanje oko 500 eozinofila / mm3.
bis-phenol-A-diglycidyl ether or triglycidylisocyanurate, or a phenolic-, hydroxyl-, amine-, carboxylate or isocyanate functional crosslinker. 
bis-fenol-A-diglicidil eter ili triglicidilizocijanurat, ili sredstvo za umreživanje s fenolnim, hidroksilnim, amino, karboksilatni, ili izocijanatnim funkcionalnim skupinama.
Additionally, the present invention encompasses a method of treating or preventing Alzheimer's Disease in a patient in need of the treatment or prevention. 
Antitijelo temeljem bilo kojeg od zahtjeva 1-4, ili 6 za upotrebu u liječenju ili sprječavanju Alzheimerove bolesti.
The compound for use of claim 1, wherein the disease or disorder is breast cancer. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je karcinom jajnika.